TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06651177: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Sponsor: T. John Winhusen, PhD · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 310 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,897,600

Rescue Site Savings

+$5,876,400

Unlock Full NCT06651177 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06651177 Rescue Dossier →